Udziały w przychodach to szacunki za quarter ended 2026-03-31, a nie dane z raportu złożonego do regulatora.
Established Pharmaceutical Products
Branded generic medicines sold outside the United States, including treatments for digestive conditions, women's health, heart and metabolic conditions, pain, and respiratory infections.
Diagnostic systems and tests
Laboratory instruments, test kits, and rapid tests used to help detect or monitor conditions such as infections, cancer, heart problems, and thyroid disorders.
Nutrition products
Infant formula, adult nutrition drinks and powders, and products used for feeding patients in healthcare institutions, including Similac, Ensure, and PediaSure.
Heart and other medical devices
Products include pacemakers, heart valves, devices used to treat narrowed blood vessels, and implanted devices for chronic pain or movement disorders.
FreeStyle Libre
A continuous glucose monitoring system with a sensor worn on the body to measure glucose levels for people with diabetes.
Cologuard
A stool-based test used to screen for colorectal cancer; Abbott discussed it on its earnings call as part of its cancer diagnostics business.
Pełne sprawozdania finansowe →
Abbott develops, makes, and sells healthcare products around the world. Its businesses include branded generic medicines sold outside the United States, diagnostic tests and equipment, nutrition products, and devices for heart conditions, diabetes, and other needs. Its buyers include healthcare providers, distributors, retailers, government agencies, and consumers.
Zbudowane z własnych raportów spółki Abbott Laboratories składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
The themes Abbott Laboratories is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
107,27 USD-1,9%zamknięcie 12 lis
Dane do 30 września 2026, z raportu 10-Q złożonego 4 listopada 2026
Abbott makes and sells medicines, diagnostic tests, nutrition products, and medical devices.
Grade B
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 40 kwartałów historii ocen spółki Abbott Laboratories. Pozostałe 38 sięgają do listopad 2016.